Literature DB >> 34181409

Structure-Activity Relationship of para-Carborane Selective Estrogen Receptor β Agonists.

David Sedlák1, Tyler A Wilson2, Werner Tjarks3, Hanna S Radomska4, Hongyan Wang4, Jayaprakash Narayana Kolla1, Zbigniew J Leśnikowski5, Alena Špičáková6, Tehane Ali3, Keisuke Ishita3, Liva Harinantenaina Rakotondraibe3, Sandip Vibhute2, Dasheng Wang2, Pavel Anzenbacher6, Chad Bennett2,7, Petr Bartunek1, Christopher C Coss4,7.   

Abstract

Selective agonism of the estrogen receptor (ER) subtypes, ERα and ERβ, has historically been difficult to achieve due to the high degree of ligand-binding domain structural similarity. Multiple efforts have focused on the use of classical organic scaffolds to model 17β-estradiol geometry in the design of ERβ selective agonists, with several proceeding to various stages of clinical development. Carborane scaffolds offer many unique advantages including the potential for novel ligand/receptor interactions but remain relatively unexplored. We synthesized a series of para-carborane estrogen receptor agonists revealing an ERβ selective structure-activity relationship. We report ERβ agonists with low nanomolar potency, greater than 200-fold selectivity for ERβ over ERα, limited off-target activity against other nuclear receptors, and only sparse CYP450 inhibition at very high micromolar concentrations. The pharmacological properties of our para-carborane ERβ selective agonists measure favorably against clinically developed ERβ agonists and support further evaluation of carborane-based selective estrogen receptor modulators.

Entities:  

Year:  2021        PMID: 34181409     DOI: 10.1021/acs.jmedchem.1c00555

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Estrogen Receptor-β Agonists Modulate T-Lymphocyte Activation and Ameliorate Left Ventricular Remodeling During Chronic Heart Failure.

Authors:  Rachel Rosenzweig; Vinay Kumar; Sahil Gupta; Oscar Bermeo-Blanco; Matthew S Stratton; Richard J Gumina; Shyam S Bansal
Journal:  Circ Heart Fail       Date:  2022-06-22       Impact factor: 10.447

2.  Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer.

Authors:  Jharna Datta; Natalie Willingham; Jasmine M Manouchehri; Patrick Schnell; Mirisha Sheth; Joel J David; Mahmoud Kassem; Tyler A Wilson; Hanna S Radomska; Christopher C Coss; Chad E Bennett; Ramesh K Ganju; Sagar D Sardesai; Maryam Lustberg; Bhuvaneswari Ramaswamy; Daniel G Stover; Mathew A Cherian
Journal:  Front Oncol       Date:  2022-04-25       Impact factor: 5.738

3.  A Novel Estrogen Receptor β Agonist Diminishes Ovarian Cancer Stem Cells via Suppressing the Epithelial-to-Mesenchymal Transition.

Authors:  Ananya Banerjee; Shurui Cai; Guozhen Xie; Na Li; Xuetao Bai; Kousalya Lavudi; Kevin Wang; Xiaoli Zhang; Junran Zhang; Srinivas Patnaik; Floor J Backes; Chad Bennett; Qi-En Wang
Journal:  Cancers (Basel)       Date:  2022-05-06       Impact factor: 6.575

Review 4.  Carboranes as unique pharmacophores in antitumor medicinal chemistry.

Authors:  Yu Chen; Fukuan Du; Liyao Tang; Jinrun Xu; Yueshui Zhao; Xu Wu; Mingxing Li; Jing Shen; Qinglian Wen; Chi Hin Cho; Zhangang Xiao
Journal:  Mol Ther Oncolytics       Date:  2022-01-10       Impact factor: 7.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.